Can a gene therapy clear the toxic tau tangle in Alzheimer's?

NCT ID NCT07764146

Not yet recruiting Disease control Sponsor: Voyager Therapeutics Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental gene therapy called VY1706 in people with early Alzheimer's disease. The goal is to see if it is safe and tolerable, and whether it can reduce tau protein buildup in the brain, a hallmark of the disease. Participants receive one of three dose levels, and researchers monitor safety and measure changes in tau biomarkers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VY1706, an experimental gene therapy given in low, mid, or high doses
What this could lead to: If successful, VY1706 could offer a new way to slow or halt Alzheimer's progression by targeting tau protein buildup in the brain.
What could go wrong: This is an early, small dose-escalation study focused on safety, so it may not prove effective. Gene therapies carry risks like immune reactions or unintended effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.